Study: Androgen Deprivation Therapy Does Not Affect Performance of Piflufolastat F 18-PET/CT

By Kerri Fitzgerald - June 15, 2022

New data presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting showed that androgen deprivation therapy (ADT) did not impact the performance of piflufolastat F 18 positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer recurrence or metastasis.

Piflufolastat F 18 is a radiopharmaceutical that targets the prostate-specific membrane antigen during imaging in men with suspected prostate cancer metastasis who are candidates for initial definitive therapy and in those with suspected recurrence based on elevated prostate-specific antigen (PSA) levels.

The researchers examined whether ADT would affect the performance of the radiopharmaceutical by evaluating piflufolastat F 18-PET/CT in 93 men with elevated PSA and radiologic evidence of local recurrence or metastatic disease. Of the entire sample, 32 patients (34.4%) were receiving concurrent ADT therapy. Each subject received a single intravenous dose of piflufolastat F 18, followed by PET/CT 1 or 2 hours later. Three independent readers evaluated the scans to determine sensitivity and positive predictive value (PPV).

Piflufolastat F 18-PET/CT had comparable sensitivity and PPV among men who were receiving ADT and those who were not, wrote the authors, led by Lawrence Saperstein, of the Yale School of Medicine.

Did you like this article?